Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Cortesi

Showing results (131-140 of 181) with videos related to

Pageof 19
Sort By:
Menopause (New York, N.Y.)|May 12, 2026
Association between risk-reducing salpingooophorectomy and bone health in women with hereditary breast and ovarian cancer syndromeSara De Vincentis, Giulia Brigante, Riccardo Cuoghi Costantini, et al.
Breast Cancer Research and Treatment|April 25, 2012
Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in ItalyLaura Ottini, Valentina Silvestri, Piera Rizzolo, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 17, 2018
Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controlsPier Mannuccio Mannucci, Alessandro Nobili, Emanuela Marchesini, et al.
Therapeutic Advances in Medical Oncology|February 22, 2021
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancerAndrea Rocca, Pietro Cortesi, Laura Cortesi, et al.
Critical Reviews in Oncology/Hematology|August 9, 2021
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific SocietiesAntonio Russo, Lorena Incorvaia, Umberto Malapelle, et al.
Critical Reviews in Oncology/Hematology|July 8, 2024
Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2Alessandra Fabi, Laura Cortesi, Simona Duranti, et al.
Familial Cancer|May 14, 2026
Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort studyGiovanni Grandi, Claudia Piombino, Giovanna Sighinolfi, et al.
Breast (Edinburgh, Scotland)|December 30, 2017
A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in ItalyValentina Silvestri, Piera Rizzolo, Veronica Zelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2025
Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 TrialHarriet Johansson, Debora Macis, Martino Oliva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2021
Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive DiseaseAndrea DeCensi, Matteo Puntoni, Harriet Johansson, et al.
Pageof 19

Showing results (131-140 of 181) with videos related to

Sort By:
Pageof 19
Menopause (New York, N.Y.)|May 12, 2026
Association between risk-reducing salpingooophorectomy and bone health in women with hereditary breast and ovarian cancer syndromeSara De Vincentis, Giulia Brigante, Riccardo Cuoghi Costantini, et al.
Breast Cancer Research and Treatment|April 25, 2012
Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in ItalyLaura Ottini, Valentina Silvestri, Piera Rizzolo, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 17, 2018
Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controlsPier Mannuccio Mannucci, Alessandro Nobili, Emanuela Marchesini, et al.
Therapeutic Advances in Medical Oncology|February 22, 2021
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancerAndrea Rocca, Pietro Cortesi, Laura Cortesi, et al.
Critical Reviews in Oncology/Hematology|August 9, 2021
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific SocietiesAntonio Russo, Lorena Incorvaia, Umberto Malapelle, et al.
Critical Reviews in Oncology/Hematology|July 8, 2024
Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2Alessandra Fabi, Laura Cortesi, Simona Duranti, et al.
Familial Cancer|May 14, 2026
Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort studyGiovanni Grandi, Claudia Piombino, Giovanna Sighinolfi, et al.
Breast (Edinburgh, Scotland)|December 30, 2017
A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in ItalyValentina Silvestri, Piera Rizzolo, Veronica Zelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2025
Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 TrialHarriet Johansson, Debora Macis, Martino Oliva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2021
Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive DiseaseAndrea DeCensi, Matteo Puntoni, Harriet Johansson, et al.
Pageof 19